1. Home
  2. LMB vs CAPR Comparison

LMB vs CAPR Comparison

Compare LMB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Limbach Holdings Inc.

LMB

Limbach Holdings Inc.

N/A

Current Price

$81.08

Market Cap

1.1B

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$33.27

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LMB
CAPR
Founded
1901
2005
Country
United States
United States
Employees
1400
N/A
Industry
Engineering & Construction
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
LMB
CAPR
Price
$81.08
$33.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$130.00
$41.38
AVG Volume (30 Days)
157.1K
1.1M
Earning Date
06-10-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
25.68
N/A
EPS
3.23
N/A
Revenue
$646,804,000.00
$22,270,465.00
Revenue This Year
$16.50
N/A
Revenue Next Year
$4.76
$17,308.50
P/E Ratio
$25.02
N/A
Revenue Growth
24.68
N/A
52 Week Low
$63.02
$4.30
52 Week High
$154.04
$40.37

Technical Indicators

Market Signals
Indicator
LMB
CAPR
Relative Strength Index (RSI) 41.01 72.07
Support Level $77.96 $22.09
Resistance Level $85.30 $40.37
Average True Range (ATR) 6.63 1.84
MACD -1.66 0.46
Stochastic Oscillator 11.78 71.58

Price Performance

Historical Comparison
LMB
CAPR

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: